Leonard Braden Michael's Form 4 filing
Aclaris Therapeutics, Inc. (ACRS) · filed Jul 31, 2024
- Accession no.
- 0001373604-24-000056
- Filed
- Jul 31, 2024
- Trade date
- Jul 30-31, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $358.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard Braden MichaelCIK 0001373603 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.303 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F3
Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.3264 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.